In the News

• Nov. 24, 2008
  

  It's official: J&J to pay $438m for Omrix Biopharm

  Omrix CEO: We believe this merger is in the best interest of Omrix's shareholders, customers and employees.

• Nov. 16, 2008
  

  Weizmann, Hebrew University top world ranking

  'The Scientist' ranks Israeli academic institutions in first, second places in its annual search 'the best places to work in academia' outside the US

• Nov. 12, 2008
  

  BioLineRx and Yissum Sign a Licensing Agreement for the Development of a Novel Compound for the Treatment of Inflammatory Bowel Disease

• Nov. 8, 2008
  

  New skin disease deemed too rare to warrant research

  The disease and defective genes have been discovered by a team at the Hadassah University Medical Center

• Nov. 2, 2008
  

  Bio Jerusalem offers grants to move to city

  The capital seeks young biomed firms.

• Oct. 30, 2008
  

  Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography

• Oct. 28, 2008
  

  BioJerusalem Announces Grant for Startup Life Science Companies Located in Jerusalem

• Oct. 26, 2008
  

  Brainsway gets FDA nod for device trial

  The company plans to begin a multi-center trial of its deep Transcanial Magnetic Stimulation device soon.

• Oct. 24, 2008
  

  Ohio and Jerusalem combine bio-forces

  Agreement aims to accelerate life science economic development

• Oct. 23, 2008
  

  Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository

  An insulin suppository represents an important development in the treatment of diabetes as it provides a painless alternative for effective insulin delivery

• Oct. 16, 2008
  

  BioOhio and BioJerusalem enter collaboration agreement

  On Thursday, October 16, BioOhio and BioJerusalem met in Beachwood, Ohio, to formalize a cooperative economic development partnership.

• Oct. 8, 2008
  

  Yissum offers new technologies that are worlds apart: computer pattern matching, and enhanced flower aroma

• Oct. 7, 2008
  

  Patience pays in biotech

  Hadasit Bio Holdings allows investors access to early stage research.

• Oct. 2, 2008
  

  Yissum Announces a Novel Method for Swift and Robust Pattern Recognition

  The novel algorithm enables very rapid recognition of a particular pattern in a fraction of the time currently available.

• Sep. 29, 2008
  

  BIOJERUSALEM WISH YOU ALL A HAPPY NEW YEAR

• Sep. 16, 2008
  

  Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform

  ORMD 0901 is being developed as an oral dosage form of a GLP1-analog aimed at improving glycemic control in adults with type 2 diabetes

• Sep. 8, 2008
  

  BioCancell's guided missile cancer therapy

• Sep. 8, 2008
  

  Hadassah doctors reduce MS symptoms with stem cells

  Transplanted neural cells derived from human embryonic stem cells reduced the clinical symptoms in animals with a form of multiple sclerosis.

• Sep. 3, 2008
  

  Hadasit pronounces guiding catheter a success

  The company is seeking partners to help finance the next stage of development.

• Aug. 28, 2008
  

  Successful Stage II Clinical Trials for New Medication Holds Hope for Cystic Fibrosis Sufferers

  The trials were conducted at Jerusalem's Hadassah University Medical Center

• Aug. 26, 2008
  

  Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare

  Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare

• Aug. 15, 2008
  

  Shaare Zedek Introduces Groundbreaking New Cardiac Procedure to Israel

  The first hospital in Israel to successfully replace heart valves using cardiac catheterization.

• Aug. 12, 2008
  

  Hadassah Research Leads

• Aug. 12, 2008
  

  Omrix Q2 profit doubles

  The biopharmaceutical company raised its full year revenue and profit guidance.

• Aug. 6, 2008
  

  Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule

  The trial demonstrated the safety and efficacy of the ORMD 0801- oral insulin capsule

• Jul. 21, 2008
  

  Gamida Cell Announces License Agreement with Amgen to Support Development and Commercialization of StemEx® for Hematological Malignancies

• Jul. 20, 2008
  

  Verto, a subsidiary of Hadasit Bio-Holdings, completes successful human clinical trial of a treatment for Lupus

  The Lupusorb™ was demonstrated to be safe and effective in removing a harmful antibody from patients’ bodies.

• Jul. 17, 2008
  

  Ancient DNA may provide key to origins of TB

  The Jericho bones DNA research is one of 11 trilateral research projects at the Hebrew University involving Palestinian, Israeli and German cooperation.

• Jul. 17, 2008
  

  Brainsway shares jump on CE Mark certification

  The company will now be able to market its device in EU countries.

• Jul. 16, 2008
  

  BiolineRX heart implant wins Windhover Top Ten award

  BL-1040 is a resorbable liquid polymer for strengthening heart muscle after a heart attack.

• Jul. 15, 2008
  

  Oramed Pharmaceuticals Raises $5 Million Through a Private Placement

  The Equity Financing was led by Montaur Capital Partners

• Jul. 15, 2008
  

  Israeli discovers microRNAs play key role in virus-human war

  Hebrew University of Jerusalem doctoral student Naama Elefant developed the unique technique for analyzing the function of microRNAs in viruses.

• Jul. 14, 2008
  

  Gamida-Cell Signs Collaboration Agreement with Biologics Delivery Systems

  Biologic Delivery Systems will supply catheters for Gamida Cell’s upcoming Phase I/II study of CardioCure™ for heart attack patients.

• Jul. 10, 2008
  

  Nobel laureate joins Oramed scientific board

  Professor Hershko was awarded the Nobel Prize in Chemistry in 2004.

• Jul. 2, 2008
  

  Octopus research sheds light on human memory function

  Research into the octopus has shed new light on how our brains store and recall memory, according to Israeli researchers.

• Jun. 26, 2008
  

  Hadassah's melanoma vaccine advances to clinical trial

  However, the developer questions its commercial viability.

• Jun. 22, 2008
  

  BioCancell Therapeutics Approves Receipt of $3.65 Million Investment

  Investment to total $0.73m in equity and $2.92m in convertible bonds; will include 3 institutional investors

• Jun. 22, 2008
  

  RNA ENGINEERING CAN COMBAT DISEASE

  Research that helps control errors in gene expression as a safer and more effective alternative to conventional drugs has won from Prof. Hermona Soreq, Dean of the Hebrew University Science Faculty one of this year's Kaye Innovation awards.

• Jun. 15, 2008
  

  Bioline schizophrenia drug begins next clinical trial

  The company expects results from the new phase 2b trial during the third quarter of 2009.

• Jun. 15, 2008
  

  Hadassah Physician Searches For New Medicine in the Oldest Germinated Date Seed

  New Research Findings Published last Thursday in "Science" Magazine

• Jun. 12, 2008
  

  Invention to prevent surgical adhesions wins Kaye Award

  A material designed to prevent adhesions following surgery, patented by Yissum, has won for Hebrew University Prof. Daniel Cohn of the Casali Instititue of Applied Chemistry first prize in this year's Kaye Awards for Innovation.

• Jun. 5, 2008
  

  Brainsway reports interim results for bi-polar treatment

  Participants in the study had not responded to previous drug treatments.

• Jun. 4, 2008
  

  Hebrew U. researchers win award for cancer therapy

  Dr. Arie Dagan and Prof. Shimon Gatt have developed molecules that kill cancers without affecting normal tissue

• May. 29, 2008
  

  Israeli device opens up the saliva diagnostic market

  An Israeli professor has developed a new saliva-based disposable device that could be used to increase the diagnostic value of saliva, enabling physicians to do away with blood and other invasive diagnostic tests

• May. 27, 2008
  

  Jerusalem lures biomed firms with grants

  BioJerusalem will allocate at least two grants of NIS 2.4 million each to life sciences companies

• May. 25, 2008
  

  The Jerusalem Development Authority Allocates, through BioJerusalem, up to 2.4 Million NIS Grant per Company to Life Science Companies Initiating or Expanding Activity in Jerusalem

  The municipal authorities in Jerusalem are the first in Israel to recognize the importance of the biomedical industry as a major growth engine for the economic development of the city

• May. 21, 2008
  

  Hadasit’s and Ramot’s LuboCollar, Designed to Help Save the Lives of Trauma Patients, Proves 100% Effective in Clinical Study

  Hadasit and Ramot will exhibit LuboCollar and other groundbreaking medical

• May. 19, 2008
  

  Biogenerics is the future says Teva's Suesskind

  The outgoing CFO spoke yesterday at Oppenheimer Israel 9th Annual Investor Conference.

• May. 19, 2008
  

  BioCancell Therapeutics, Inc. and Pro-Pharmaceuticals, Inc. to work together to develop cancer treatment

  The collaboration will be initially focused on pre-clinical development

• May. 13, 2008
  

  Artificial Heart Transplanted at Hadassah

  Physicians at Hadassah Ein Kerem successfully transplanted an artificial heart in a 40-year-old woman from the Jerusalem area.

• May. 11, 2008
  

  TK signal, a subsidiary of Hadasit Bio Holdings Ltd, received Helsinki committee approval and initiated preliminary clinical trial to evaluate the efficacy of an existing drug against malignant cells from patients with various hematologic malignancies

  The preliminary trial will last six months and will be conducted on 40 patient's samples

• May. 8, 2008
  

  Oral insulin co Oramed in presidential presentation

  President Bush and Sergey Brin will attend.

• May. 6, 2008
  

  Israeli scientist holds out hope of diagnosis by cell phone

  Israeli researchers have discovered a way to transmit medical images via a cellular phone, opening up the possibility of providing sophisticated diagnosis and treatment to millions of people who live a long distance from modern medical centers.

• Apr. 30, 2008
  

  Sweat ducts tell all, Israeli researchers find

  The question, 'how do you feel?' could become redundant in years to come after Israeli researchers discovered a method to remotely sense the physiological and emotional state of human beings using tiny radio antennas already in our skin.

• Apr. 17, 2008
  

  Hadasit, Harvard affiliate immune system drug trial succeeds

  The drug is orally administered and the goal is to treat immune mediated diseases.

• Apr. 15, 2008
  

  Doctors hope to check up on patients by tuning in to micro radio antennas

  Scientists at the Hebrew University's applied physics department have discovered a method for remote sensing of people's physiological and emotional state

• Apr. 14, 2008
  

  Chief Scientist funds new biotech projects

  30% of the Chief Scientist's R&D budget goes to the life sciences

• Apr. 7, 2008
  

  Can Seaweed Mend a Broken Heart?

  New research indicates that an alginate-based biomaterial injected into heart attack victims may stave off further damage

• Apr. 6, 2008
  

  Yissum 2007 revenue rises 27%

  Yissum 2007 revenue rises 27% The company ended the year with a profit but will not disclose how much.

• Apr. 6, 2008
  

  Hadassah Biotech Park gets off the ground

  Hadasit has signed the first lease in the new project.

• Mar. 27, 2008
  

  Hadassah donors hear the high-tech talk

  A fund raiser for Hadassah Ein Karem hospital included presentations by local start-ups.

• Mar. 24, 2008
  

  First Patient Successfully Undergoes Breakthrough Treatment for Acute Myocardial Infarction Developed by BioLineRx

  BioLineRx Initiates Phase 1/2 for BL-1040 novel myocardial implant for the treatment of Acute MI

• Mar. 23, 2008
  

  Life sciences co ConjuGate raises $1.8m

  The company is developing an antifungal for treating AIDS patients.

• Mar. 17, 2008
  

  Clal Biotech looks to TASE to fund Biocancell stake

  The company seeks to raise NIS 60 million in an offering of shares and debt.

• Mar. 13, 2008
  

  Oramed looks to phase IIa oral insulin trial

  The company reported that it successfully completed the Phase 1b clinical trial.

• Mar. 11, 2008
  

  Yissum Announces Hebrew University Genetic Resource for Studies of Common Diseases

  The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

• Mar. 9, 2008
  

  BioCancell to test drug on 3 more cancers

  The company has applied to test BC-819 on pancreatic, ovarian, and liver cancers.

• Feb. 28, 2008
  

  Israeli researchers help reveal electronic structure of DNA

  The work may result in faster and cheaper ways to decode the sequence of human DNA.

• Feb. 28, 2008
  

  Yissum Announces the Discovery of a Novel Small Molecule With Potent Anti-Metastatic Activity

  Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.

• Feb. 25, 2008
  

  Hadassah breaks chain of BRCA mutation

  A breakthrough in-vitro fertilization plus pre-implantation genetic diagnosis (PGD) of fraternal twins

• Feb. 25, 2008
  

  A new clinical trial in treatment of post-traumatic stress disorder (PTSD) at Hadassah

  Transcranial Magnetic Stimulation (TMS) Treatment for Post Traumatic Stress Disorder (PTSD) and Depression

• Feb. 18, 2008
  

  Brainsway magnetic anti-depressant passes test

  CEO Uzi Sofer: We can file for CE Mark certification on the basis of these results.

• Feb. 12, 2008
  

  Clal Biotech to buy further Biocancell stake

  Biocancell develops targeted therapy to destroy cancer cells.

• Feb. 4, 2008
  

  BioLineRx Announces Positive Results from Phase 2a Trial of BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia

  Phase 2a results show statistically significant improvement in PANSS and CGI scores with minimal side effects – Phase 2b expected to begin in Q2 2008 -

• Jan. 24, 2008
  

  Oramed begins oral insulin trial

  The company has begun Phase Ib trial to find the optimal dosage.

• Jan. 24, 2008
  

  Sol-Gel sells sunscreen activity to Merck

  The activity was sold for more than $10 million, plus royalties on product sales.

• Jan. 23, 2008
  

  Hadasit, Harvard Medical School, Hadassah Medical Organization and Brigham and Women’s Hospital Collaborate for the First Time in a New Joint Venture to Develop a New Orally Administered Therapy for Autoimmune Diseases

  A Phase I safety and efficacy study in healthy patients will begin in February 2008 at Hadassah University Medical Center in Jerusalem.

• Jan. 22, 2008
  

  Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study

  The plant cell expressed protein demonstrated full protection from organophosphate poisoning

• Jan. 20, 2008
  

  Brainsway interim trial for blepharospasm successful

  The company is conducting small trials of its transcranial magnetic stimulation treatment on a range of neurological problems.

• Jan. 15, 2008
  

  Forticell in stem cell collaboration with Korea's CJ Corp.

  Forticell was created by the merger of Hapto Biotech and Ortec.

• Jan. 13, 2008
  

  Biocancell to begin Phase IIb trial for bladder cancer drug

  The FDA approved the trial at 5 Israeli hospitals and one in Arizona.

• Jan. 9, 2008
  

  Yissum and Eucalyptus Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

  Molecule is an antioxidant that overcomes the blood-brain barrier

• Jan. 2, 2008
  

  Brainsway happy with anti-depressant interim results

  This is the company's last trial before applying to the FDA for a large trial at several medical centers.

• Dec. 25, 2007
  

  Yissum Spins-Off Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology

  Jerusalem-based Yissum has formed a spin-off company Nanolymf, which will be dedicated to advancing a nanotechnology controlled-release drug delivery platform.

• Dec. 16, 2007
  

  Cell Cure raises $3 million

  The firm will continue its stem cell research, and not be limited to a specific disease.

• Dec. 10, 2007
  

  BioLineRx In-Licenses Novel Formulation BL-5010 for the Non-Surgical Removal of Skin Lesions

  A non-invasive treatment for skin lesions

• Dec. 5, 2007
  

  Drugs and vaccines by special delivery

  One of Israel's leading biochemists, Prof. Yechezkel Barenholz of the Hebrew University's Hadassah Medical School, has used liposomes to design better drug delivery systems that extend and improve the lives of cancer patients around the world.

• Dec. 5, 2007
  

  Biocancell cancer fighting drug succeeds in trial

  The biotech company's share rose over 13% on the news.

• Dec. 2, 2007
  

  TK Signal, a Hadasit Bio-Holdings Portfolio Company, Signs a Licensing Agreement for New Oncology Therapy.

  The company has concluded a binding MOU to license and develop new technology, developed by Dr. Miya Levite, for the treatment of several types of cancer.

• Nov. 22, 2007
  

  Hadassah's innovative treatment for multiple sclerosis: transplanting stem cells from patient's bone marrow

  New Multiple Sclerosis Center launched at Hadassah this week

• Nov. 21, 2007
  

  Positive results for InCure cancer diagnostic test

  The test uses blood samples to diagnose breast and colon cancers.

• Nov. 15, 2007
  

  BioLineRx In-Licenses Anti-Cancer Compound BL-4060

  The compound considerably reduces the size of pancreatic, prostate and breast tumors

• Nov. 14, 2007
  

  Hadasit and Anadis to Form Joint Venture Company to Develop Therapeutic Treatments for Inflammatory Diseases, Infectious Diseases and Cancer

  The new company will be called Immuron and the products will be based on a combination of IP from Hadasit and Anadis

• Nov. 6, 2007
  

  First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma

  Patients are now being enrolled in the U.S. for the Gamida Cell-Teva Joint Venture ExCell trial studying StemEx® as an alternative treatment for bone marrow transplants.

• Nov. 5, 2007
  

  Belgian co licenses Hebrew U biodegradable plastic

  The plastic is produced from protein-rich crops such as soy beans, canola

• Oct. 29, 2007
  

  Omrix begins Adhexil clinical trials

  Adhexil is a human fibrin-based sealant after gynecological surgery.

• Oct. 29, 2007
  

  BioLineRx Announces Positive Results from Phase 2a Interim Trial Analysis of BL-1020 for the Treatment of Patients with Schizophrenia

  Phase 2a interim results suggest that BL-1020 has the potential to become an effective antipsychotic with minimal side effects -

• Oct. 23, 2007
  

  Biocancell drug effective against several cancers

  The company will now apply to the FDA for Phase I human clinical trials for BC-819.

• Oct. 21, 2007
  

  A spoonful of sugar

  Biotech start-up ConjuGate's antifungal therapy helps the medicine go down.

• Oct. 17, 2007
  

  BiolineRX mulls dual listing on Nasdaq

  CEO Morris Laster: I didn’t immigrate to Israel to emigrate back

• Oct. 1, 2007
  

  BioLineRx In-Licenses Novel Peptide BL-4050 for the Treatment of Cancer

  The peptide is expected to have a wide spectrum of activity against many types of cancer types

• Sep. 24, 2007
  

  Biocancell cancer drug trial shows good results

  The company expects to begin a Phase IIb trial.

• Sep. 24, 2007
  

  Hadasit Conducts Advanced Study of Fluorescent Whitening Agents as an Anti-Water Mold Disinfectant to Combat Global “Winter Kill” Fish Epidemics

  Early data demonstrate that certain fluorescent whitening agents are non-carcinogenic and effective Saprolegnia parasitica disinfectants in fish.

• Sep. 5, 2007
  

  Hadasit commences Phase II trial of stroke treatment

  Early data shows that the virtual reality system helps patients suffer less pain.

• Sep. 2, 2007
  

  Teva to invest in stem cell start-up Cell Cure

  The Hadasit Bio portfolio company previously received funding from the Michael J. Fox Foundation.

• Aug. 27, 2007
  

  BioLineRx In-Licenses Novel Drug for the Treatment of Acute Kidney Injury

  The compound was shown to be effective for the treatment of AKI in pre-clinical trials

• Aug. 23, 2007
  

  Brainsway widens scope of its magnetic stimulation products

  The company will begin a trial of its TMS system to treat post traumatic stress disorder.

• Aug. 13, 2007
  

  Teva buys Asthma treatment rights from Yissum

  The treatment was found in testing to have eliminated four different types of allergic diseases in mice.

• Aug. 12, 2007
  

  Yissum and Protalix BioTherapeutics Sign Agreement to License Acetylcholinestrase Development Technology

  Protalix BioTherapeutics to Explore Biodefense and Civilian Applications with Researchers from Hebrew University of Jerusalem

• Aug. 8, 2007
  

  Biocancell completes Phase I clinical trial

  The trial is for a prostate cancer treatment.

• Aug. 8, 2007
  

  Brainsway reports positive interim results of trial

  The company has developed Deep TMS - a transcranial magnetic stimulation device - for the treatment of bipolar disorder and depression.

• Aug. 6, 2007
  

  Oramed raises $2m in private placement

  The company is developing an oral insulin capsule for treating diabetes

• Aug. 1, 2007
  

  Hebrew University’s Yissum signs deal with Neocrine Biosciences

  Valnoctamide and its individual stereoisomers have a potential $15 billion worldwide market for treating neurological and psychiatric disorders.

• Jul. 31, 2007
  

  Antitope Ltd., (UK) and ProtAb Ltd. (Israel) – an HBL Portfolio Company, Announce Antibody Research Agreement

  Antitope will generate a humanized antibody for the treatment of RA and other autoimmune diseases

• Jul. 23, 2007
  

  Hadasit cervical collar passes Phase I safety trials

  The study was registered with the National Institute of Health (NIH) and operated under the guidelines of both the NIH and the Israeli Ministry of Health.

• Jul. 17, 2007
  

  Brainsway gets permit for Parkinson’s trial

  The company is currently conducting clinical trials of its device to treat depression.

• Jul. 16, 2007
  

  BioLineRx Announces Results of Clinical Receptor-Occupancy Study of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia

  Study determines that BL-1020 significantly blocks dopamine receptor – direct evidence of antipsychotic efficacy -

• Jun. 25, 2007
  

  BioJerusalem Launches Activities

  Jerusalem Development Authority allocates initial 10 million NIS to BioJerusalem

• Jun. 7, 2007
  

  Jerusalem's BreathID IPO is 37% oversubscribed

  The company's offering was oversubscribed despite the absence of an underwriter and institutional tender.

• Jun. 5, 2007
  

  BiolineRX, Pan Atlantic Bank set up $6m research fund

  The companies intend to invest in 8-10 projects in fields related to BiolineRX.

• May. 30, 2007
  

  Hadasit Announces Hadassah Hospital’s New Clinical Research Center

  The Center will be located at the new BioTechnology Park in Ein Kerem

• May. 28, 2007
  

  Hadasit Bio raises investment from Consensus Business Group

  The group manages a $500 million fund for investment in technology commercialization companies.

• May. 24, 2007
  

  J&J to distribute Medinol stents

  Johnson & Johnson subsidiary Cordis estimates that the bare metal stents will be available outside the US in the second half of 2007.

• May. 17, 2007
  

  FDA approves Omrix sealant for vascular surgery

  Johnson and Johnson subsidiary Ethicon will market Evicel.

• May. 9, 2007
  

  Gamida Cell and NovaThera to collaborate on lung repair

  The companies will develop cell therapeutic treatments for lung repair and regeneration.

• May. 8, 2007
  

  Shaare Zedek Medical Center Signs Historic Academic Affiliation Agreement With Hebrew University

  As a result of the agreement and with the resulting expansion of the Hebrew University faculty, the medical school will be able to cater to a higher number of students.

• Apr. 26, 2007
  

  Four are better than one

  Tiltan has developed an anti-cancer platform that attacks the cancer's supply line instead of the growth itself.

• Apr. 25, 2007
  

  Michael J. Fox Foundation puts faith in Israeli Parkinson's research

  Cell Cure Neurosciences and Proneuron Biotechnologies have been awarded grants under a new program started by the foundation

• Apr. 22, 2007
  

  Verto begins Phase I/II trial of Lupus drug

  Verto has developed a combined device and drug, the Lupusorb column.

• Apr. 11, 2007
  

  Yissum sells its Holdings in BioCancell Therapeutics to Clal Biotechnology Industries

  CBI will purchase 24% of the cancer-drug developer; Yissum keeps its royalties agreement

• Apr. 4, 2007
  

  Teva to recruit 200 for new Jerusalem plant

  The plant's exports will amount to $700 million a year

• Mar. 13, 2007
  

  An Israeli Biotech Company Plays the Field

  Flush with investors' capital, BioLineRX screens hundreds of promising compounds, then develops a handful that might make profitable drugs

• Mar. 7, 2007
  

  Brainsway to conduct human trial for Deep TMS

  The trial will test the effectiveness of its Deep Transcranial Magnetic Stimulation device its marijuana rehab.

• Feb. 25, 2007
  

  Hadasit Bio to invest $1.8m in 5 portfolio cos

  The companies are Tolarex, ProtAb, Kahr Medical, Verto and InCure.

• Feb. 11, 2007
  

  Diagnostic co BreathID to raise $10m on TASE

  BreathID has developed a non-invasive a multi-test platform for diagnosing and monitoring a range of diseases and disorders of the digestive system.

• Jan. 25, 2007
  

  BiolineRX to raise $50m on TASE

  This will be the largest IPO ever by a biomedical company on TASE.

• Jan. 8, 2007
  

  Clal Biotechnology is strategic investor in Thrombotech

  CBI will invest $50,000 in Trombotech's blood clot treatment